Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Type 2 Diabetes Mellitus · Irritable Bowel Syndrome · LXRX

LEXICON PHARMACEUTICALS

LEXICON PHARMACEUTICALS, INC.

LEXICON PHARMACEUTICALS clinical programs — 51 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
8800 Technology Forest, The Woodlands, TX 77381, US HQ
1995 Founded
282 Employees
Public company Type
LXRX · NYSE Ticker
Company details
Status
Public
HQ
8800 Technology Forest, The Woodlands, TX 77381, US
Founded
1995
Employees
282
Programs
51
Drugs
27
Patents
102
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

LEXICON PHARMACEUTICALS projects

51 ClinicalTrials.gov programs sponsored by LEXICON PHARMACEUTICALS.

LEXICON PHARMACEUTICALS has 51 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

51 programs

Clinical programs

Page 1 of 2

  1. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  3. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  4. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  5. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Heart Failure

    phase 3 small molecule terminated

    2 trials

  6. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  7. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  8. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  9. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic

    phase 3 small molecule active

    1 trial

  10. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  11. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  12. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Carcinoid Syndrome

    phase 3 small molecule completed

    5 trials

  13. 250 mg LX1033 tablets

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  14. 75 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  15. Gemcitabine

    LEXICON PHARMACEUTICALS, INC.

    Locally Advanced Unresectable Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  16. LX1031 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  17. LX3305 low dose

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  18. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. LX6171 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  20. LX7101 (0.125%)

    LEXICON PHARMACEUTICALS, INC.

    Primary Open-angle Glaucoma

    phase 2 small molecule completed

    1 trial

  21. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  22. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  23. Placebo (blinded)

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  24. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes

    phase 2 small molecule active

    2 trials

  25. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Cardiac Failure Aggravated

    phase 2 small molecule terminated

    1 trial

  26. Telotristat Etiprate

    LEXICON PHARMACEUTICALS, INC.

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  27. 250 mg capsule

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 1 small molecule completed

    1 trial

  28. 300 mg LX4211 (150 mg tablets)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  29. 400 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  30. 50 mg LX3305 QD

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  31. 500 mg [14C]-LX1606

    LEXICON PHARMACEUTICALS, INC.

    Carcinoid Syndrome

    phase 1 small molecule completed

    1 trial

  32. Fexofenadine

    LEXICON PHARMACEUTICALS, INC.

    Drug Interactions

    phase 1 small molecule completed

    1 trial

  33. LX3305

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  34. LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    2 trials

  35. LX4211

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  36. LX4211 400 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  37. LX4211 400 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  38. LX4211 800 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  39. Omeprazole 40 MG

    LEXICON PHARMACEUTICALS, INC.

    Drug-drug Interaction

    phase 1 small molecule completed

    1 trial

  40. Schedule A

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  41. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  42. Sotagliflozin (SOTA) followed by 3 drugs in a random order

    LEXICON PHARMACEUTICALS, INC.

    Platelet Function and Reactivity Tests

    phase 1 small molecule active

    1 trial

  43. Telotristat Ethyl

    LEXICON PHARMACEUTICALS, INC.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  44. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Drug Interactions

    phase 1 small molecule completed

    2 trials

  45. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    QT Interval

    phase 1 small molecule completed

    1 trial

  46. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  47. Treatment A (rosuvastatin)

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  48. Treatment A digoxin

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does LEXICON PHARMACEUTICALS have?

51 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.